Fundraising Foxatai Life Sciences — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Cambrian Bio is a clinical-stage drug development company creating precision therapeutics that target metabolic pathways which decline with age, such as AMPK and mTOR.
BiotechHealthtechLongevityNew York, US
James Peyer(CEO, Founder, Board Director)inMark Nuttall(Chief Business Officer)inRuth Thieroff-Ekerdt(Chief Medical Officer)inBill DeVaul(Chief Legal Officer)in
BoardMaryanna Saenko(Director)in
Board seatChristian Angermayer· per SEC Form D · $37.6M raise · filed Jan 2025
Co-investorsAlumni VenturesCatalio Capital Management, LPDEFTA PartnersFJ LabsFuture VenturesKhosla Ventures+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.